On Monday, FreeSeas Inc (NASDAQ:FREE)’s shares showed no change to $0.0175. With its recent share price change, FREE market value has reached roughly $2.09 billion. Its most recent quarter balance sheet showed the company is standing at a -0.10 current ratio and possess -1.99 as debt to equity ratio. The stock’s performance in 1 month is -41.67% and its volatility for the same period is 23.33%.
FreeSeas Inc., through its auxiliaries, provides drybulk shipping services. Its vessels carry various drybulk commodities, such as iron ore, grain, and coal, in addition to bauxite, phosphate, fertilizers, steel products, cement, sugar, and rice. Its fleet comprises of five Handysize vessels and one Handymax vessel.
HP Inc (NYSE:HPQ)’s shares dropped -0.85% to $11.63. The market capitalization of HP Inc (NYSE:HPQ) is $21.02 billion with the total traded volume of the company is 8.05 million. Turning to market valuation, the Price-to-Earnings ratio is 4.69, the Price-to-Sales ratio is 0.20 and the Price-to-Book ratio is finally 0.76. The dividend yield amounts to 4.30 percent and the beta ratio has a value of 1.50.
HP Inc. provides products, technologies, software, solutions, and services to individual consumers and small- and medium-sized businesses (SMBs), in addition to the government, health, and education sectors worldwide. It operates through Personal Systems and Printing segments.
pSivida Corp. (NASDAQ:PSDV)‘s shares surged 8.47% to $4.74.
pSivida Corp. (PSDV) (PVA.AX) declared that it plans to file for EU marketing approval of Medidur™ for chronic non-infectious uveitis of the posterior segment of the eye (posterior uveitis) based on data from a single pivotal trial as a result of the high statistical significance achieved in its first Phase 3 clinical trial. The U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) advised pSivida that, compriseent with the published Points to Consider (PtC) of the European Agency for Evaluation of Medicinal Products, an application for a product treating a condition like posterior uveitis could be based on statistically compelling and clinically relevant results from just one pivotal trial. The MHRA recently offered this specific advice in formal minutes of a meeting with pSivida held on October 29, 2015 (preceding to the Company’s receipt of topline results for its first Phase 3 clinical trial). With those results now accessible, pSivida plans to confirm with the MHRA the plan to file for EU marketing approval of Medidur based on one trial.
“We are delighted with this advice offered by the MHRA. We expect the high statistical significance of the efficacy data, clinical benefits and positive safety data in our first trial will meet the criteria used by MHRA and other EU regulatory authorities to approve a product on the basis of a single pivotal study,” said Paul Ashton, president and CEO of pSivida Corp. “Using data from a single clinical trial would significantly accelerate our filing for EU marketing approval for Medidur. As posterior uveitis affects a similar number of people in the EU and the U.S., accelerated approval in the important EU market would be very beneficial to us.”
pSivida’s first Phase 3 clinical trial for Medidur for Posterior Uveitis met its primary endpoint of prevention of recurrence of disease at six months with exceptional statistical significance (p < 0.00000001, intent to treat). Exploratory analyses of Medidur-treated eyes contrast to control at six months also showed statistical significance: improvement in visual acuity (gain of 15 or more letters on the Early Treatment Diabetic retinopathy Study (ETDRS) Eye Chart) (p = 0.011), reduction in treatment with systemic treatments (steroids, immunosuppressants and biologics) (p < 0.01), and prevention of loss of vision (loss of 15 or more letters) (p < 0.0001). Safety data at six months comparing Medidur-treated eyes to control eyes were also positive, counting the observation of modest relative enhances in intraocular pressure (IOP) above 21mmHg and cataract surgeries.
pSivida Corp. develops sustained-release drug-delivery products for treating eye diseases in the United States and the United Kingdom. It offers ILUVIEN, an injectable, sustained-release micro-insert for use in treating vision impairment associated with diabetic macular edema; and Retisert for the treatment of posterior uveitis.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.